Last reviewed · How we verify
NCT03333174
Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 3
NA trial testing Cardiorespiratory monitoring in Infant,Premature in 25 participants. Completed in 1 July 2021.
1 July 2021
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 9 April 2018 |
| Primary completion | 1 July 2021 |
| Estimated completion | 1 July 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cardiorespiratory monitoring
Conditions studied
- Infant,Premature — all drugs for Infant,Premature →
Sponsor
University of Alabama at Birmingham
Who can join
Adults 1 Day to 98 Days, any sex, with Infant,Premature. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine if servo-controlled oxygen environment is associated with reduction in (a) bradycardia events, (b) hypoxemic time, (c) bradycardia time, (d) apneic episodes
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Control of breathing in preterm infants on incubator oxygen or nasal cannula oxygen.
Travers CP, Chahine R, Nakhmani A, Aban I, et al · · 2025 · PMID 39147903 · DOI 10.1038/s41390-024-03460-5
Verify or expand the search:
- PubMed search for NCT03333174
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cardiorespiratory monitoring
Trials testing the same drug.
- NCT04569643 — Periodic Limb Movement Syndrome in Patients With Cerebral Small Vessel Disease. · unknown
- NCT03333161 — Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 2 · NA · completed
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03333174 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 21 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03333174.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing